News and Updates
Dupilumab gets FDA nod for moderate-to-severe eczema in teens
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Sanofi/Regeneron) for adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis poorly controlled with topical prescription therapies or when those therapies are not advisable. It can be used with or without topical corticosteroids.
To continue reading this article
Continue reading your article with a eMediNexus account.